This section of the Zynex Medical InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Zynex Medical assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQZYXI
| Beta | 0.67 |
|---|---|
| Shares Outstanding | 38.5M |
| Average Volume (10 days) | 247.2K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 3 | |
|---|---|---|
| Buy | 0 | |
| Hold | 0 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Daniel J. Moorhead Chief Financial Officer | (554) Dispose Jan 30, 2023 |
|---|---|
Thomas Sandgaard Director, President, CEO and Chairman, Ten Percent Owner | (554) Dispose Jan 30, 2023 |
Anna Lucsok Chief Operating Officer | (223) Dispose Jan 30, 2023 |
Anna Lucsok Chief Operating Officer | (5,536) Dispose Jan 27, 2023 |
Anna Lucsok Chief Operating Officer | 5,000 Dispose Jan 27, 2023 |
